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Kupﬀer cells in non-alcoholic fatty liver disease: The emerging viewq
Gyo¨rgy Baﬀy*
Brigham and Women’s Hospital and VA Boston Healthcare System, Harvard Medical School, Section of Gastroenterology,
150 S. Huntington Ave., Boston, MA 02130, USANon-alcoholic fatty liver disease (NAFLD) has become the most common liver disorder of our times. Simple steatosis, a
seemingly innocent manifestation of NAFLD, may progress into steatohepatitis and cirrhosis, but this process is not well
understood. Since NAFLD is associated with obesity and insulin resistance, mechanisms that link lipid metabolism to
inﬂammation oﬀer insights into the pathogenesis. An important parallel between obesity-related pathology of adipose tis-
sue and liver pertains to the emerging role of macrophages and evidence is growing that Kupﬀer cells critically contribute
to progression of NAFLD. Toll-like receptors, in particular TLR4, represent a major conduit for danger recognition linked
to Kupﬀer cell activation and this process may be perturbed at multiple steps in NAFLD. Steatosis may interfere with
sinusoid microcirculation and hepatocellular clearance of microbial and host-derived danger signals, enhancing responsive-
ness of Kupﬀer cells. Altered lipid homeostasis in NAFLD may unfavourably aﬀect TLR4 receptor complex assembly and
sorting, interfere with signalling ﬂux redistribution, promote ampliﬁcation loops, and impair negative regulation including
alternative activation of Kupﬀer cells. These events are further promoted by altered adipokine secretion and reactive oxy-
gen species production. Speciﬁc targeting of these interactions may provide more eﬀective strategies in the treatment of
NAFLD.
Published by Elsevier B.V. on behalf of the European Association for the Study of the Liver.
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Non-alcoholic fatty liver disease (NAFLD) has
become the most common liver disorder in the United
States and other developed countries, aﬀecting over
one-third of the population [1]. This remarkable increase
in NAFLD prevalence coincides with the obesity epi-
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condition. Being both the source and the result of insu-
lin resistance, however, steatosis may be associated with
increased risk for cardiovascular morbidity [2]. Steatosis
may also alter the natural history of other liver diseases
such as chronic viral hepatitis [3]. Most importantly, in
about 15% of all NAFLD cases steatosis may evolve
into steatohepatitis, a medley of inﬂammation, hepato-
cellular injury, and ﬁbrosis, often resulting in cirrhosis
and even hepatocellular cancer [4]. Although this full
sequence of progression is relatively rare, the over-
whelming prevalence of NAFLD predicts a major
healthcare burden.
NAFLD was originally deﬁned by Ludwig and col-
leagues as a condition indistinguishable by histology
from alcoholic steatohepatitis, although most patients
carried the hallmarks of obesity and the metabolic syn-
drome [5]. Subsequently, the term ‘NAFLD’ was intro-
duced to denote the entire spectrum of obesity-relatedociation for the Study of the Liver.
G. Baﬀy / Journal of Hepatology 51 (2009) 212–223 213fatty liver disease [6]. The pathogenesis of NAFLD is
often interpreted by the ‘double-hit’ hypothesis [7].
Accordingly, hepatocellular lipid accumulation presents
the ‘ﬁrst hit’, followed by a ‘second hit’ in which pro-
inﬂammatory mediators and reactive oxygen species
(ROS) induce inﬂammation, hepatocellular injury, and
ﬁbrosis [8]. While this is a useful conceptual framework,
our understanding of the cellular and molecular mecha-
nisms that deﬁne NAFLD and guide therapeutic
approaches remains insuﬃcient. Liver disease is often
characterized by complex interactions between resident
and recruited cells that may determine the form and
severity of pathologic changes and this principle cer-
tainly applies to NAFLD.
As our knowledge is expanding on the role of macro-
phages in danger recognition, immune tolerance, and
lipid homeostasis, the signiﬁcance of these cellular path-
ways as they pertain to liver macrophages in NAFLD is
increasingly appreciated. This review summarizes evi-
dence and considerations for the involvement of Kupﬀer
cells in the pathogenesis of NAFLD, while the reader is
referred to current literature on other emerging aspects
of the disease. Since isolation, culture, and transfection
of Kupﬀer cells is challenging, some conclusions origi-
nate from observations on other macrophage popula-
tions. Moreover, species-speciﬁc diﬀerences require
caution when extrapolating experimental ﬁndings to
human disease. These limitations notwithstanding, rap-
idly growing insights into this exciting ﬁeld invite a
review of the most pertinent advances.2. Kupﬀer cells in health and disease: general
considerations
Kupﬀer cells constitute the largest component of the
reticuloendothelial system, representing 80–90% of all
tissue macrophages in the body [9]. Central to innate
immunity, Kupﬀer cells are responsible for swift con-
tainment and clearance of exogenous particulate and
immunoreactive material that is perceived as foreign
and harmful [10]. Similar to other macrophages, Kupﬀer
cells also sense endogenous molecular signals that may
result from perturbed homeostasis of the host. Kupﬀer
cells rapidly recognize potential danger from both
sources and undergo activation. Through a series of
co-ordinated cellular events, activated Kupﬀer cells are
enabled to (1) launch biochemical attack and initiate
interactions with hepatocytes and other liver cells by
releasing a variety of biologically active mediators
including cytokines, chemokines, eicosanoids, proteo-
lytic enzymes, ROS, and nitric oxide; (2) recruit and
retain non-resident cellular players to the liver such as
neutrophils, natural killer (NK) T lymphocytes, NK
cells, and blood monocyte-derived macrophages by
expressing adhesion molecules and secreting chemo-kines; (3) engulf, ingest, and eliminate solid particles,
including microorganisms, apoptotic cells, and cell deb-
ris; and (4) process and present antigens to attract cyto-
toxic and regulatory T cells and therefore also
contribute to adaptive immunity [10–15]. These func-
tions of Kupﬀer cells need rigorous control to avoid
escalation of the inﬂammatory response. Liver damage
may either result from inability of Kupﬀer cells to prop-
erly recognize and eliminate danger molecules or from
excessive mobilization of cytotoxic mechanisms and fail-
ure to halt inﬂammation. Accordingly, Kupﬀer cells are
predisposed to modulate the pathogenesis of NAFLD in
many ways.3. Topologic and functional heterogeneity of Kupﬀer cells
Kupﬀer cells represent about 10% of the resting total
liver cell population and are strategically located in the
liver sinusoids, which provide the anatomical structure
for capillary-level conﬂuence of portal vein and hepatic
artery tributaries [10,12]. Thus, Kupﬀer cells come in
contact with a variety of molecular substances such as
nutrients, microorganisms, cell debris, immune com-
plexes, and toxic agents carried by hepatic circulation.
While initially described as ‘ﬁxed tissue macrophages’,
Kupﬀer cells migrate between the sinusoids and the
space of Disse [16] and orchestrate a cross-talk between
various resident and recruited cells of the liver.
Speciﬁc to their position within the liver acinus,
Kupﬀer cells diﬀer in their population density, morpho-
logical characteristics, and physiological functions
[17,18]. This distribution correlates with the acinar con-
centration gradient of immunoreactive substrates and
regulatory factors. Large Kupﬀer cells are located in
the periportal zone with exposure to incoming molecular
signals. Accordingly, large Kupﬀer cells exhibit higher
phagocytosis, lysosomal protease activity, and output
of biologically active mediators than smaller Kupﬀer
cells in mid-zonal and perivenous areas [17,18]. Large
Kupﬀer cells can be identiﬁed by cell surface expression
of the scavenger receptor CD163, also described as ED2
antigen in the rat [19]. By contrast, glycosylated trans-
membrane protein CD68 (ED1) is located in lysosomes
and can be detected in all Kupﬀer cells regardless of
their acinar location [20].
While changing abundance and distribution of Kupf-
fer cells may reﬂect anomalous gain or loss of function,
the importance of zonal heterogeneity remains to be
seen in NAFLD. Increased presence of CD68-positive
Kupﬀer cells correlates with the histological severity of
human NAFLD [21]. Moreover, aggregates of enlarged
Kupﬀer cells are present in perivenular regions of the
liver of NASH patients as compared to diﬀuse distribu-
tion seen in simple steatosis [22]. Selective depletion of
large Kupﬀer cells by administration of gadolinium
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uptake and increased toxicity of the rare-earth metal
compound in these cells [23,24], markedly attenuates
liver injury induced by thioacetamide [25], carbon tetra-
chloride [26], alcohol [27] and ischemia/reperfusion [28],
indicating that ED2-positive Kupﬀer cells critically con-
tribute to liver damage in these conditions. Similarly,
administration of liposome-encapsulated dichlorometh-
ylene bisphosphonate (clodronate), which eliminates
90% of large Kupﬀer cells and 50% of small Kupﬀer cells
[29], reduces hepatotoxicity in response to concanavalin
[30], alcohol [31], and acetaminophen [32]. In experi-
mental NAFLD induced by methionine/choline deﬁ-
cient diet, clodronate eﬀectively blunts all histological
evidence of steatohepatitis [33]. These observations indi-
cate that activation of Kupﬀer cells positioned at the
‘frontline’ is an essential element in the pathogenesis of
NAFLD similar to other types of liver injury.
An increasing pool of macrophages is characteristic
to many pathologic conditions of the liver including ste-
atohepatitis [22]. Contribution of blood monocyte-
derived macrophages to this pool and to the heterogene-
ity of Kupﬀer cells in steatohepatitis remains unclear
since there is currently no reliable marker to distinguish
resident macrophages from recruited macrophages in
the liver. The ﬁnding that resident macrophages in lean
adipose tissue originate from a CCR2CX3CR1hi
monocyte pool whereas recruited adipose tissue macro-
phages originate from a pool of CCR2+CX3CR1low cir-
culating monocytes [34] may prove helpful in this eﬀort.
Weakened or absent Kupﬀer cells may also associate
with deleterious eﬀects. Thus, impaired clearance of LPS
and other danger molecules by Kupﬀer cells may result
in accelerated liver injury and this mechanism needs to
be considered in NAFLD. In support of this concept,
imaging studies by contrast-enhanced ultrasound [35]
or super-paramagnetic iron oxide (SPIO)-magnetic reso-
nance imaging [36] suggest impaired phagocytic function
of Kupﬀer cells in NAFLD. Moreover, depletion of
Kupﬀer cells by GdCl3 or clodronate may shift the aci-
nar distribution of phagocytosis, alter the balance
between pro- and anti-inﬂammatory cytokines, and
interfere with liver regeneration, reﬂecting the functional
complexity and phenotypic plasticity of Kupﬀer cells
[37–39].4. Disease-speciﬁc pathways of molecular pattern
recognition in NAFLD
The molecular signals received by Kupﬀer cells such
as structural motifs of proteins, lipids, and nucleic acids
that originate from invading microorganisms are com-
monly referred to as pathogen-associated molecular pat-
terns (PAMPs) [14,40]. Kupﬀer cells also detect
components released from host cells that are injured,dying, or undergoing malignant transformation. These
endogenous protein and non-protein ligands belong to
damage-associated molecular patterns (DAMPs) and
are alternatively termed alarmins [41]. Endogenous
sources of DAMPs include heat shock proteins, high
mobility group box 1 protein, breakdown products of
the extracellular matrix (e.g., hyaluronan, ﬁbrinogen,
and ﬁbronectin), and non-protein substrates (e.g., uric
acid) [41].
Exogenous and endogenous DAMPs are identiﬁed by
a large variety of pattern recognition receptors (PRPs)
[14,40,41]. Toll-like receptors (TLRs) comprise a family
of highly conserved PRPs that recognize bacterial, viral,
and fungal components [40,42]. Of these, TLR4 has a
central role in Kupﬀer cell activation. TLR4 responds
to lipopolysaccharide (LPS) or endotoxin, the prototyp-
ical PAMP located in the outer wall of Gram-negative
bacteria [40,43]. Recognition of LPS initiates assembly
of the plasma membrane-tethered TLR4 signalling com-
plex [41]. Downstream targets of TLR4 signalling are
determined by selective recruitment of cytosolic sorting
and signalling adaptor proteins via interactions between
Toll-IL-1 receptor (TIR) domains [44–46]. Thus, TLR4
activation may engage myeloid diﬀerentiation factor 88
(MyD88) and TIR domain-containing adaptor protein
or MyD88 adaptor-like (TIRAP/Mal), leading to the
activation of nuclear factor (NF)-jB and AP-1 tran-
scription factors [40,41,43]. By contrast, TLR4 may sig-
nal through TIR domain-containing adaptor inducing
interferon-b (TRIF), and TRIF-related adaptor mole-
cule (TRAM) primarily to activate interferon regulatory
factor 3 (IRF3) and promote the transcription of inter-
feron-b [40,41,43].
There is substantial evidence that TLR4-mediated
cellular events escalate liver injury in steatosis [40,43].
Recent studies indicate that TLR4 sorting speciﬁcity
may reﬂect the etiology of fatty liver disease. Thus, the
protective eﬀect of TLR4 deﬁciency against alcohol-
induced liver injury is replicated in IRF3/ mice,
but not in MyD88/ mice [47,48]. Preferential TLR4
sorting to the IRF3 cascade has also been reported in
mouse livers after warm hepatic ischemia/reperfusion
injury [49]. Conversely, altered MyD88 signalling may
associate with NAFLD. Thus, the C558T single-nucleo-
tide polymorphism variant of TIRAP gene impairs
MyD88-mediated TLR signalling and correlates with
lack of liver ﬁbrosis in a cohort of patients with
biopsy-proven NAFLD, while confers no protection
from alcohol-induced liver injury [50]. These preliminary
observations suggest that TRAM/TRIF-dependent
interferon responses are the primary target of alcohol
in the liver, while altered activation of TIRAP/Myd88-
dependent pathways may dominate the progression of
NAFLD. Notably, proper balance between TIRAP/
Myd88-mediated cytokine production and TRAM/
TRIF-mediated interferon responses may be necessary
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in silico simulation predicts signalling ﬂux redistribution
between alternative Myd88 and TRAM activation and
this concept has been validated in mouse macrophages
[51]. Due to the rather ubiquitous presence of TLR4
among various types of liver cells, the speciﬁc role of
Kupﬀer cells in diﬀerential activation of TLR4 pathways
remains to be seen. It must also be noted that endoge-
nous ligands such as certain fatty acids and other alar-
mins may also be linked to TLR4 sorting speciﬁcity, a
question particularly relevant to NAFLD.5. Ampliﬁcation of danger signals in NAFLD
LPS is considered a pivotal exogenous danger mole-
cule in the pathogenesis of fatty liver disease. Circulating
LPS levels are elevated and the liver exhibits remarkable
sensitivity to LPS in most experimental models of
NAFLD [52–54]. Whereas translocation of LPS from
the gut lumen to portal circulation in alcoholic liver
injury may result from direct alcohol toxicity disrupting
the barrier function of intestinal epithelium [55],
increased exposure to intestinal LPS has also been con-
sidered in NAFLD pathogenesis. Thus, dietary factors
(e.g., increased fructose ingestion) may contribute to
altered intestinal motility, bacterial overgrowth, and
increased epithelial permeability in both experimental
and human NAFLD [54,56]. Improvement of liver dis-
ease by administering probiotics in these conditions pro-
vides indirect support to this concept [57,58].
Disturbed hepatic clearance is a major mechanism
that may contribute to increased LPS levels in NAFLD,
in particular when facing higher loads via the portal cir-
culation. Scavenger receptors are transmembrane pro-
teins located in the lipid raft domains (caveolae),
which bind lipoproteins and are able to remove and
detoxify foreign substances including LPS [59]. Kupﬀer
cells express high levels of class A scavenger receptors
(SR-A), which have aﬃnity to modiﬁed (e.g., oxidized,
acetylated, or glycated) low density lipoprotein (LDL),
but do not bind native lipoproteins [59]. In addition,
SR-A receptors are capable of LPS uptake [60]. Impor-
tantly, binding of modiﬁed LDL and LPS to SR-A may
trigger an inﬂammatory response by Kupﬀer cells. Since
SR-A promotes cell adhesion, it may also contribute to
recruitment and retention of various cells at the site of
inﬂammation [59]. In contrast, hepatocytes express class
B scavenger receptors such as SR-B1, which binds both
native and modiﬁed lipoproteins in addition to mediat-
ing LPS uptake [61]. Recent studies on SR-B1-null mice
indicate that hepatocellular SR-B1 activity may consid-
erably lower the LPS burden [62]. Others found that
b2-integrin (CD11b/CD18) and TIRAP also mediate
hepatocellular LPS uptake [63]. As a result, physiologic
hepatocellular activity may ‘mop up’ LPS and thwartinﬂammatory signalling cascades in Kupﬀer cells [62].
This concept may be extended to modiﬁed LDL and
other danger signals and it is reasonable to speculate
that impaired clearance of DAMP molecules by fatty
hepatocytes may enhance activation of Kupﬀer cells
and contribute to the pathogenesis of NAFLD.
Insuﬃcient control of danger recognition may also
lead to increased LPS sensitivity. Since TLR4 is the pri-
mary conduit for cellular eﬀects of LPS, stringent regu-
lation of TLR4 signalling is essential to avoid excessive
inﬂammatory response [64]. LPS tolerance, or hypore-
sponsiveness to repeated LPS exposure is a consequence
of these anti-inﬂammatory feedback circuits [65,66].
TLR4-mediated responses are controlled at multiple lev-
els, most proximally by inhibition of the TLR4 signal-
ling complex via homotypic TIR–TIR interactions
[44,67,68]. Tyrosine phosphatases provide yet another
way of inhibitory regulation. Protein tyrosine phospha-
tase-1B (PTP1B), SH2-containing protein tyrosine phos-
phatase 1 (SHP1), and the dual speciﬁcity (tyrosine/
threonine) MAPK phosphatase MKP-1 appear essential
in balancing TLR-mediated responses [69–71]. Finally,
suppressor of cytokine signalling protein SOCS-1 is a
versatile inhibitor induced by elevated cytokine levels
and targeting multiple steps of Myd88-dependent path-
ways [72]. SOCS-1 may directly interact with phosphor-
ylated TIRAP/Mal and initiate proteasomal
degradation [73]. How these mechanisms speciﬁcally
pertain to the function of Kupﬀer cells need further
elucidation.6. Kupﬀer cell functions in altered lipid homeostasis
Hepatocellular accumulation of lipids is a key mor-
phologic feature of NAFLD. Lipidomic analysis of
human liver tissue is a promising novel approach to
associate abnormal fat composition with various stages
of NAFLD. Thus, total and damaged phospholipids
are more abundant in simple steatosis at the expense
of triglycerides [74], while increased ratio of stearic to
arachidonic acid in NASH may correlate with ﬁbrosis
[75]. Altered abundance and composition of liver tissue
lipids may modulate the biological activity of Kupﬀer
cells in NAFLD through a number of mechanisms.
First, the space-occupying eﬀect of fat-laden hepatocytes
may lead to impaired sinusoidal perfusion [76]. Leuko-
cytes trapped in narrowed sinusoids may increasingly
engage Kupﬀer cells in the microvascular inﬂammatory
response [76]. Second, excessive exposure of Kupﬀer
cells to fatty acids may modulate pathways of inﬂamma-
tion and insulin resistance through interaction with cell
surface receptors and intracellular mediators [77]. Third,
anomalous deposition of lipids in the plasma membrane
may alter the structure of lipid raft domains and inter-
fere with clustering and function of cell surface receptors
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functioning of intracellular membranes as seen with free
cholesterol loading of mitochondria [79]. Finally, abun-
dant or abnormal lipids may confound recognition of
fatty hepatocytes as dangerous and promote adverse
interactions with Kupﬀer cells [15]. Nevertheless, exis-
tence of a lipid-derived quintessential alarmin expressed
or released by steatotic hepatocytes remains speculative.
Recent ﬁndings indicate that TLR-mediated recogni-
tion of fatty acid moieties is an important mechanism by
which lipids regulate pathways of inﬂammation and
innate immunity [78]. Depending on fatty acid composi-
tion, the outcome of this eﬀect may be highly variable.
Saturated fatty acids, implicated in the development of
chronic conditions such as atherosclerosis, have been
shown to activate TLR4 signalling in adipocytes and
macrophages through both Myd88-dependent and
TRIF-dependent pathways [80,81]. By contrast, polyun-
saturated fatty acids inhibit these events in several cell
types including macrophages [81]. Consequently,
TLR4 is a sensor of endogenous fatty acid levels and
composition, and Kupﬀer cells most likely beneﬁt from
this ability.
Emerging evidence indicates that altered cholesterol
metabolism may also contribute to the pathogenesis of
NAFLD. Rats fed choline-deﬁcient (but methionine-
suﬃcient) diet supplemented with high amounts (2%)
of cholesterol develop impaired mitochondrial function,
characterized by accumulation of free cholesterol, gluta-
thione depletion, and increased susceptibility to TNF-a
and Fas-mediated liver injury [79]. Moreover, choles-
terol metabolism may directly aﬀect the function of
Kupﬀer cells. Thus, high-fat diet fed to LDL receptor-
deﬁcient mice rapidly results in signiﬁcant hepatic
inﬂammation, but only if the diet contains cholesterol
[82]. Presence of ‘foamy’ Kupﬀer cells suggests that scav-
enging of modiﬁed lipoproteins may induce this early
inﬂammatory response [82]. While these ﬁndings need
to be extrapolated to human NAFLD with caution, they
point to the importance of altered cholesterol metabo-
lism. In addition, some of these observations challenge
the ‘second-hit’ concept since steatosis is not necessarily
a forerunner of hepatic inﬂammation as these events
may develop simultaneously [82,83].7. Alternative macrophage activation in NAFLD
Alternatively activated macrophages (also termed M2
as opposed to the classical M1 or pro-inﬂammatory phe-
notype) represent another critical pathway for resolu-
tion of the inﬂammatory response [84]. The
coordinated program of alternative activation is primar-
ily stimulated by Th2 cytokines IL-4 and IL-13, and
characterized by cell surface expression of M2 signature
genes such as the mannose receptor, arginase-1, and dec-tin-1 [84]. There is evidence that steatosis promotes Th1
polarization of the cytokine balance favouring innate or
classic activation of macrophages in NAFLD. Thus, in
experimental and human NAFLD alike, the pool of
hepatic NKT cells is reduced and liver tissue level of
Th1 cytokines, such as TNF-a, IL-12, IL-18, and inter-
feron-c, is elevated [85–88].
Peroxisome proliferator-activated receptors PPARa,
PPARc, and PPARd and liver X receptors LXR-a and
LXR-b are members of the nuclear hormone receptor
superfamily of transcription factors that coordinate
complex genetic programs of metabolism [89,90]. Ther-
apeutic use of synthetic ligands to target these receptors
and exploit their biological functions is increasing. Ben-
eﬁcial eﬀects of PPARc in hepatocellular lipid homeo-
stasis have prompted large clinical trials to assess
impact on NAFLD and these eﬀorts have been recently
reviewed elsewhere [91]. However, the recognition that
nuclear hormone receptors link lipid metabolism to
alternative activation of macrophages adds a new
dimension to their potential use in the treatment of
NAFLD [84,92].
While PPARc promotes alternative activation of
macrophages that contribute to valuable metabolic
changes such as improved insulin sensitivity [93,94],
recent research indicates that PPARd is speciﬁcally
required for a similar program in Kupﬀer cells
[95,96]. Thus, signature gene expression of PPARd-deﬁ-
cient Kupﬀer cells is greatly reduced in livers of obese
mice and in response to IL-4 stimulation [95,96]. More-
over, PPARd ablation results in severe steatosis and
insulin resistance [95,96]. Notably, the eﬀect of PPARd
in Kupﬀer cells is modulated by fatty acids [95] and
may fail due to altered lipid homeostasis and hepatic
microenvironment in NAFLD. Thus, hepatocytes as a
previously unsuspected source of Th2 cytokines stimu-
late M2 gene expression in Kupﬀer cells and this
important regulatory circuit may be altered in steatosis
[96]. These ﬁndings raise the intriguing possibility that
speciﬁc targeting of PPARd in Kupﬀer cells to induce
alternative activation may improve both inﬂammation
and steatosis in NAFLD. One important caveat is that
the M2 phenotype includes stimulation of the extracel-
lular matrix that may contribute to hepatic ﬁbrosis
[97].8. Adipokines and the liver inﬂammatory response
Adipose tissue produces a large variety of humoral
factors, collectively termed adipokines, which include
pro-inﬂammatory cytokines, e.g., TNF-a and IL-6,
and polypeptide hormones, e.g., leptin, resistin, visfa-
tin, and adiponectin [98,99]. These substances have
important regulatory roles in cellular and biochemical
events that deﬁne the pathogenesis of obesity and
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[100]. Leptin, the archetypal adipokine, primarily acts
by suppressing food intake and promoting energy
expenditure [101]. In addition, leptin has marked
eﬀects on the innate immune response by promoting
activation and phagocytosis of macrophages, presum-
ably through JAK/STAT signalling [102]. Pro-inﬂam-
matory and pro-ﬁbrogenic eﬀects of leptin have also
been observed in Kupﬀer cells and stellate cells
[98,103,104]. Accordingly, hyperleptinemia associated
with obesity may contribute to progression of
NAFLD, although this issue remains controversial
[105]. Recent studies indicate that resistin may cause
lipid accumulation in macrophages by up-regulating
the SR-A scavenger receptor [106]. Visfatin, the char-
acteristic adipokine of mesenteric adipose tissue, also
has pro-inﬂammatory properties by inducing TNF-a
and IL-6 in monocytes [107]. Further studies are
needed to fully understand the eﬀect of these newer
adipokines in Kupﬀer cells.
While many adipokines are associated with adverse
biological functions, adiponectin, the most abundant
adipose-derived hormone, seems to have a protective
eﬀect in NAFLD. Full-length adiponectin (Acrp30)
and its cleavage derivative, globular adiponectin (gAc-
rp), have been credited with anti-diabetic, anti-inﬂam-
matory, and anti-atherogenic properties [108].
Accordingly, adiponectin and its receptors, the ubiqui-
tous AdipoR1 and the predominantly hepatocellular
AdipoR2, are expressed at reduced levels in patients
with obesity, insulin resistance, type-2 diabetes, and
NAFLD [109,110]. Moreover, serum levels of adipo-
nectin fall further in NASH compared to uncompli-
cated steatosis [111], suggesting that adiponectin may
prevent ‘second-hit’ events in the pathogenesis of
NAFLD.
Adiponectin stimulates hepatic fatty acid oxidation
and ketogenesis, while it inhibits cholesterol and tri-
glyceride synthesis [108]. Whereas these metabolic
activities primarily occur in hepatocytes, adiponectin
has potent anti-inﬂammatory eﬀects in macrophages.
Thus, adiponectin is able to suppress the eﬀects of
LPS in macrophages, including activation of NF-jB
and ERK1/2 [112–114]. Similarly, adiponectin prevents
LPS-mediated inﬂammatory signalling in Kupﬀer cells
[115]. These anti-inﬂammatory eﬀects of adiponectin
may involve IL-10 signalling pathways [116]. Interest-
ingly, NADPH oxidase is a major IL-10 target in var-
ious cell systems including macrophages [117].
Moreover, adiponectin controls hepatic ROS levels
through inhibition of NADPH oxidase in experimental
alcohol-induced liver injury (Laura E. Nagy, personal
communication). These ﬁndings suggest that the bene-
ﬁcial eﬀects of adiponectin in NAFLD may also occur
through controlling intracellular ROS production and
activation of Kupﬀer cells.9. ROS biology of Kupﬀer cells
Cellular reactive oxygen species (ROS) are byprod-
ucts of normal aerobic metabolism [118,119]. ROS
may cause macromolecular toxicity, necessitating an
elaborate antioxidant defense system. The toxic eﬀects
of ROS, however, also protect the host from invading
microorganisms as observed in the cellular events of
innate immunity [120,121]. Moreover, ROS regulate sig-
nalling cascades in a large variety of physiologic cellular
responses including pathways of danger recognition
[122]. This dual biological function of ROS has been
termed antagonistic pleiotropy [123]. Accordingly,
ROS contribute to the function of Kupﬀer cells and
other macrophages at multiple levels.
A pivotal source of ROS in inﬂammatory cells is the
NADPH oxidase or NOX [124]. Rapid release of ROS
in response to LPS and other microbial stimuli in Kupf-
fer cells and other macrophages occurs through the spe-
cialized phagocyte oxidase gp91phox or NOX2 [121].
Activated NOX2 produces superoxide, a major form
of ROS that assists microbial killing and signals to
redox-sensitive targets such as thioredoxin, protein
kinase C, ERK family members, and NF-jB [120,125].
Oxidative injury in livers of NOX2-deﬁcient mice trea-
ted with alcohol [126] or with the genotoxic carcinogen
diethylnitrosamine [127] is greatly reduced, indicating
that NOX2 is essential to the pathogenesis. By contrast,
acetaminophen-induced hepatotoxicity still occurs in
gp91phox/ mice along with increased levels of mito-
chondrial oxidized glutathione to the same extent as in
wild type mice, suggesting that NOX2 is not the source
of ROS in this setting [128]. Similarly, NOX2 seems
irrelevant in methionine/choline-deﬁcient diet-induced
experimental NAFLD, since NOX2 deﬁciency has no
eﬀect on liver tissue lipid peroxidation, steatosis, and
ﬁbrosis [129].
ROS are also produced at other intracellular sites
(e.g., mitochondria, peroxisomes, microsomal cyto-
chrome P450 system) that may aﬀect redox-sensitive
eﬀector pathways in Kupﬀer cells. Mitochondria are
the largest source of metabolically derived ROS
[130,131]. Substrate oxidation by respiring mitochondria
generates a proton gradient that maintains the electro-
chemical potential (Dwm) across the mitochondrial inner
membrane [132]. The energy of Dwm can be either used
for ATP synthesis (oxidative phosphorylation) or dissi-
pated as heat via proton leak in a process termed uncou-
pling [132]. The respiratory chain also produces
superoxide due to electron spin-oﬀ and incomplete
reduction of molecular oxygen, which is more likely to
occur at higher Dwm [130,133]. Thus, regulation of
Dwm may control mitochondrial ROS, a function
recently associated with uncoupling proteins [134,135].
Of all uncoupling proteins, UCP2 has the broadest tis-
sue distribution with abundance in cells of the immune
218 G. Baﬀy / Journal of Hepatology 51 (2009) 212–223system [134,136]. As further discussed below, UCP2
overexpression suppresses ROS production and the acti-
vation of Kupﬀer cells and other macrophages [137–
139], while UCP2 inhibition or ablation results in
increased ROS, release of pro-inﬂammatory cytokines,
and persistent activation of NF-jB [140–142].
Little is known about the interaction of mitochon-
drial and non-mitochondrial ROS-generating systems,
although these functions may overlap. Thus, antigen-
presenting ability of Kupﬀer cells is impaired to similar
degree when ROS production is inhibited at diﬀerent
intracellular sites such as NADPH oxidase, mitochon-
dria, or cytosolic xanthine oxidase [143]. Furthermore,
anti-microbial and pro-inﬂammatory activity is greatly
augmented in ucp2/ macrophages as a result of
uncontrolled mitochondrial ROS production [141].
Plausibly, ROS from any cellular source may similarly
aﬀect antioxidant defense and redox-sensitive signalling
pathways in Kupﬀer cells. Notably, Kupﬀer cells have
lower antioxidant capacity than hepatocytes, assuming
therefore a higher impact of ROS-mediated regulatory
mechanisms [144].10. Uncoupling protein-2 and activation of Kupﬀer cells
UCP2 has been considered in the pathogenesis of
NAFLD since its identiﬁcation [145]. Although hepatic
UCP2 primarily resides in Kupﬀer cells and its presence
in hepatocytes is negligible under normal conditions
[146], UCP2 becomes markedly abundant in hepatocytes
of genetically obese (ob/ob) mice and following high-fat
diet [147,148], while Kupﬀer cells and other macro-
phages have diminished UCP2 in these conditions
[148,149]. The clinical signiﬁcance of cell-speciﬁc altera-
tions of UCP2 expression in experimental NAFLD is
not entirely understood. Since large amounts of UCP2
interfere with ATP synthesis [147], fatty hepatocytes
with up-regulated UCP2 may have an energetic disad-
vantage as demonstrated during acute challenges by
Fas-mediated hepatotoxicity [149] and ischemia/reperfu-
sion injury [150,151]. By contrast, down-regulation of
UCP2 may enhance the responsiveness of Kupﬀer cells
in fatty liver, consistent with increased activity of mac-
rophages in which UCP2 is inhibited or ablated [139–
141].
LPS is a powerful inhibitor of UCP2 expression in
macrophages [139,141,148], suggesting that TLR4-med-
iated signalling may utilize mitochondrial ROS in ampli-
fying circuits. Indeed, a positive feedback loop has
recently been identiﬁed in LPS-mediated TLR4 signal-
ling that involves augmented activation of JNK and
p38 by mitochondrial ROS in peritoneal macrophages
of ucp2/ mice [152]. These ﬁndings indicate that
UCP2 may act as a physiological break to ROS-sensitive
components of TLR4 signalling such as JNK, p38, andNF-jB. Increased susceptibility to even small amounts
of LPS has been considered in the pathogenesis of
NAFLD [85,153] and ROS-mediated ampliﬁcation of
TLR4 signalling may contribute to this phenomenon
as a result of insuﬃcient UCP2 action in Kupﬀer cells.
Recently, Zhou and co-workers suggested an interest-
ing mechanism that may further clarify the role of UCP2
in NAFLD [154]. These authors describe profound
structural abnormalities and impaired respiratory activ-
ity of liver mitochondria in adiponectin-deﬁcient mice
with pre-existing steatosis [154]. Protection from LPS-
induced hepatocellular injury by adenovirus-mediated
replenishment of adiponectin is abolished if these mice
are also made UCP2-deﬁcient, indicating that in this
model UCP2 is critical to the beneﬁcial eﬀects of adipo-
nectin. In the absence of liver cell-speciﬁc studies, how-
ever, it remains unclear if UCP2 deﬁciency primarily
prevents adiponectin from regulating hepatocellular
lipid metabolism or interferes with anti-inﬂammatory
eﬀects of adiponectin in Kupﬀer cells. Nonetheless, evi-
dence is mounting that dysregulation of UCP2 alters the
balance of pro- and anti-inﬂammatory mechanisms and
NAFLD may beneﬁt from restoration of mitochondrial
ROS control in Kupﬀer cells.
Based on above considerations, use of antioxidants to
prevent and treat advanced NAFLD appears warranted.
Interestingly, however, many trials have failed to show
signiﬁcant beneﬁts from antioxidant therapy in NAFLD
as most recently reviewed by Younossi [91]. Mitochond-
rially targeted antioxidants may represent a novel strat-
egy for limiting ROS-mediated pathology in NAFLD.
Thus, mitoQ, a synthetic analog of coenzyme Q10 (ubi-
quinol/ubiquinone), selectively accumulates in the mito-
chondrial matrix and eliminates ROS by continual
redox cycling [155], while SS-31 is a cell-permeable aro-
matic-cationic peptide targeted to the inner mitochon-
drial membrane where it acts as a potent local
antioxidant [156,157]. These compounds have proved
helpful in early trials for neurodegenerative disorders
associated with mitochondrial dysfunction [158]. In
addition, mitoQ protects against organ damage in a
LPS-peptidoglycan model of sepsis [159]. It will be inter-
esting to see the impact of this approach on controlling
ROS-dependent Kupﬀer cell responses in NAFLD.11. Concluding remarks
One of the unmet challenges of NAFLD is to satis-
factorily predict its progression from simple steatosis
into steatohepatitis. This transition represents a mile-
stone in the natural history with a considerable proba-
bility for developing end-stage liver disease.
Elucidation of molecular and cellular events that may
lead to this outcome is therefore critically important.
Fortunately, the past few years have brought remark-
Fig. 1. Scheme for dysfunctional activation of Kupﬀer cells in NAFLD. Pattern recognition receptors of Kupﬀer cells such as TLR4 may be increasingly
exposed to exogenous and endogenous danger signals (e.g., LPS, excess fatty acids, modiﬁed lipoproteins) via the portal circulation, enhanced by lack of
hepatocellular clearance. Pattern recognition pathways may intensify due to altered sorting and signalling, impaired inhibitory circuits, or ampliﬁcation of
redox-sensitive signalling loops. Adipokine imbalance may contribute to these events including low adiponectin levels that fail to suppress intracellular
ROS generation. Fat-laden hepatocytes may compromise sinusoid microcirculation leading to entrapment of inﬂammatory cells. Finally, steatosis may
shift away Kupﬀer cells from alternative activation. Please see details in the text. Solid lines, pro-inﬂammatory eﬀects; dotted lines, anti-inﬂammatory
mechanisms. Malfunction at one or more steps may promote ‘second hit’ responses, while cellular targeting of these checkpoints has the potential for
identifying novel treatment strategies in NAFLD.
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genesis, often by extension of research in adipose tissue
biology, obesity, and insulin resistance. These eﬀorts
point to the intricate relationship of innate immune sys-
tem and lipid homeostasis in NAFLD with a prominent
role for Kupﬀer cells and a number of biochemical and
cellular mechanisms involved (Fig. 1). The mist contin-
ues to clear and it is now time to take advantage of what
we already know and develop new ways of predicting,
preventing, and treating advanced NAFLD.References
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